The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers
出版年份 2016 全文链接
标题
The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers
作者
关键词
-
出版物
Scientific Reports
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-09-19
DOI
10.1038/srep33710
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Small-Molecule Protein-Protein Interaction Inhibitor of PARP1 That Targets Its BRCT Domain
- (2015) Zhenkun Na et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- CETSA: a target engagement assay with potential to transform drug discovery
- (2015) Annika Jenmalm Jensen et al. Future Medicinal Chemistry
- Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation
- (2015) Yosuke Togashi et al. Journal of Thoracic Oncology
- A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
- (2015) Elayne Chan-Penebre et al. Nature Chemical Biology
- Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors
- (2015) Marica Peron et al. PLoS One
- Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays
- (2015) Ban Xiong Tan et al. Scientific Reports
- Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase
- (2015) Tian-Ying Xu et al. Scientific Reports
- Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
- (2015) Nathan F. Moore et al. Oncotarget
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
- (2014) Scott C. Bresler et al. CANCER CELL
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
- (2014) Daria Zdzalik et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation
- (2014) Cesar A. Perez et al. LUNG CANCER
- Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
- (2014) Kilian V. M. Huber et al. NATURE
- The cellular thermal shift assay for evaluating drug target interactions in cells
- (2014) Rozbeh Jafari et al. Nature Protocols
- BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo
- (2014) Longchuan Bai et al. PLoS One
- Control of ALK (wild type and mutated forms) phosphorylation: Specific role of the phosphatase PTP1B
- (2013) M.C. Boutterin et al. CELLULAR SIGNALLING
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation
- (2013) Ramesh Narayanan et al. PLoS One
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Presence of anaplastic lymphoma kinase in inflammatory breast cancer
- (2013) Fredika M Robertson et al. SpringerPlus
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma
- (2012) Samar A. Hegazy et al. CELLULAR SIGNALLING
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- The battle against ALK resistance: successes and setbacks
- (2012) Claudia Voena et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
- (2012) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anaplastic lymphoma kinase in human cancer
- (2011) Antonella Barreca et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib in Anaplastic Large-Cell Lymphoma
- (2011) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
- (2011) S. C. Bresler et al. Science Translational Medicine
- Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
- (2010) T. Martinsson et al. CANCER RESEARCH
- -catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2010) M. Anand et al. HAEMATOLOGICA
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
- (2009) Maria Paola Martelli et al. AMERICAN JOURNAL OF PATHOLOGY
- Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry
- (2009) Fang Wu et al. AMERICAN JOURNAL OF PATHOLOGY
- High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours
- (2008) Helena Carén et al. BIOCHEMICAL JOURNAL
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started